

I. Requirements for Prior Authorization of Ophthalmics, Anti-Inflammatories

A. <u>Prescriptions That Require Prior Authorization</u>

Prescriptions for Ophthalmics, Anti-Inflammatories that meet any of the following conditions must be prior authorized:

1. A non-preferred Ophthalmics, Anti-Inflammatory. See the Preferred Drug List (PDL) for the list of preferred Ophthalmics, Anti-Inflammatories at: https://papdl.com/preferred-drug-list.

B. Review of Documentation for Medical Necessity

In evaluating a request for prior authorization of a prescription for an Ophthalmics, Anti-Inflammatory, the determination of whether the requested prescription is medically necessary will take into account whether the beneficiary:

 For a non-preferred Ophthalmics, Anti-Inflammatory, has a history of therapeutic failure of or a contraindication or an intolerance to the preferred Ophthalmics, Anti-Inflammatories approved or medically accepted for the beneficiary's diagnosis

NOTE: If the beneficiary does not meet the clinical review guidelines listed above but, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary, the request for prior authorization will be approved.

C. Clinical Review Process

Prior authorization personnel will review the request for prior authorization and apply the clinical guidelines in Section B. above to assess the medical necessity of a prescription for an Ophthalmics, Anti-Inflammatory. If the guidelines in Section B. are met, the reviewer will prior authorize the prescription. If the guidelines are not met, the prior authorization request will be referred to a physician reviewer for a medical necessity determination. Such a request for prior authorization will be approved when, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary.



Prescriber Signature:

Highmark Wholecare Pharmacy Division Phone 800-392-1147 Fax 888-245-2049

NON-PREFERRED MEDICATION PRIOR AUTHORIZATION FORM (form effective 01/01/20)

NON	<u>I-PREFERREI</u>	J MEDICATION PRIOR	AUTHURIZATI	<u>ON FURIVI</u>	(form e	effective 01/01/20	IJ
□New request □	Renewal request	# of pages:	Prescriber name:				
Name of office contact:	Specialty:						
Contact's phone number:			NPI:			State license #:	
LTC facility contact/phon	Street address:						
Beneficiary name:			Suite #:	City/State/Zip:			
Beneficiary ID#:		DOB:	Phone:		Fax:		
Medication will be billed	Place of Service: Hospital Provider's Office Home Other						
Please refer to https://papdl.com/preferred-drug-list for the list of preferred and non-preferred medications in each Preferred Drug List class.							
Non-preferred medication name:		Dosage form: Strength:					
Directions:			Quan	tity:	Refills:		
Diagnosis (submit documentation):					Dx code (required):		
Has the beneficiary taken the requested non-preferred medication in the past 90 days? (submit documentation)							
documentation (e.g., recent chart/clinic notes, diagnostic evaluations, lab results, etc.) supporting this non-preferred request. Treatment failure or inadequate response with preferred medication(s) (include drug name, dose, and start/stop dates): Unacceptable side effects, hypersensitivities, or other intolerances to preferred medication(s) (include description and drug name(s)): Contraindication to preferred medication(s) (include description and drug name(s)):							
Unique clinical or age-specific indications supported by FDA approval or medical literature (describe):							
Absence of preferred medication(s) with appropriate formulation (list medical reason formulation is required):							
Drug-drug interaction with preferred medication(s) (describe):							
Other medical reason(s) the beneficiary cannot use the preferred medication(s) (describe):							
For renewal requests of previously approved medications, submit documentation of tolerability and beneficiary's clinical response.							
PLEASE FAX COMPLETED FORM TO HIGHMARK WHOLECARE – PHARMACY DIVISION							

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.

Date: